STOK Stoke Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why STOK matters now
Stoke Therapeutics, Inc. (STOK) is a US stock in Healthcare. The latest InvestLog snapshot shows $31.38 with -4.42% on the session and $1.95B in market capitalization; recent performance reads 1-month +3.47% and YTD -2.33%.
The latest financial table shown here is Q1 2026, with revenue of $6.2M, net income of $-50.0M, and EPS of $-0.79. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -7.6%.
The latest indexable market news headline is "Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $36.00; recent insider activity includes Allan Jonathan filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.95
P/S
60.18
EV/EBITDA
-10.84
DCF Value
$-47.81
FCF Yield
-7.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
90.4%
Operating Margin
-577.5%
Net Margin
-529.2%
ROE
-48.8%
ROA
-38.3%
ROIC
-45.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.2M | $-50.0M | $-0.79 |
| Q4 2025 | $1.4M | $-57.9M | $-0.99 |
| FY 2025 | $184.4M | $-6.9M | $-0.12 |
| Q3 2025 | $10.6M | $-38.3M | $-0.65 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$41.40
Target (Median)
$36.00
Target Range
$35.00 - $60.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.19
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.